Talimogene laherparepvec: first-in-class oncolytic immunotherapy

Published on November 30, 2016   44 min

Other Talks in the Series: Immunotherapy of Cancer

0:00
Hello, my name is Kevin Harrington. I work at the Institute of Cancer Research in London. I have a long-standing interest in the development of oncolytic viruses as cancer therapies. Today, I will be discussing Talimogene Laherparepvec: a First-in-Class Oncolytic Immunotherapy.
0:18
Here are my disclosures.
0:27
For many years, we have been interested in the use of viruses as potential therapies for cancer. And on this slide, you can see a small number of viruses that have been in active preclinical and clinical evaluation in the last two decades. The rest of this talk is going to focus on a single example of this which is the Herpes simplex virus, which is now a registered therapy with an approval for the treatment of melanoma in the USA, in Europe, and in Australasia.
Hide

Talimogene laherparepvec: first-in-class oncolytic immunotherapy

Embed in course/own notes